aCon is specialising in the design and production of self-service terminals for postal services. The company was founded in 2005. Syddansk Kapital invested in 2005.
www.acon.dk

iMotions develops and produces emotion sensitive software. The company was founded in 2005. Syddansk Kapital invested in the company in 2005.
www.imotionsglobal.com

Action Pharma develops drug candidates in the inflammation area. The company was founded in 2000. INCUBA Venture invested in 2003.
www.actionpharma.com

FCMB develops non-invasive prenatal diagnostic methods based on fetal cells isolated from maternal blood. The company was founded in 2005. INCUBA Venture invested in 2005.
www.fcmb.dk

Fluxome Sciences develops and optimizes the biotechnological production methods of bio products in yeast. The company was founded in 2002. INCUBA Venture invested in 2005.
www.fluxome.com

Medotech develops computer based treatment for persons suffering from bruxism. The company was founded in 2003. Syddansk Kapital invested in 2006.
www.medotech.dk

Proxeon develops nano scale cromatography equipment and high-capacity software for protein analysis. The company was founded in 2002. Syddansk Kapital invested in 2006.
www.proxeon.com

RSP develops a no-blood dependent optical system for measuring blood sugar levels in diabetes patients. The company was founded in 2006. Syddansk Kapital invested in 2006.
www.rspsystems.com

Quantibact provides a diagnostic system for fast detection of bacteria. The company was founded in 2004. INCUBA Venture invested in 2006.
www.quantibact.com

SMB develops, manufactures and markets rapid diagnostic equipment that enables veterinarians to perform point-of-care testing. Point-of-care testing provides several benefits for the veterinarian such as improved service level, additional revenue line and access to vital patient information immediately.
www.smb.dk

Mirrx Therapeutics holds fundamental IP to so-called blockmirs that are capable of blocking single microRNA:mRNA interactions, i.e. capable of preventing a microRNA from regulating one particular mRNA, while still allowing the microRNA to regulate all its other mRNA targets.
www.mirrx.dk

Tina Holding ApS primary activity is to acquire technologies in the life science segment, as well as making direct investments in companies which primarily acquired technologies used.

P.t. the company has invested in QuantiBact A/S and Mirrx Therapeutics A/S
www.vecata.dk